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Sir, We write as senior scientists about a problem vital to the scientific enterprise and prosperity. 
Nowadays, funding is a lengthy and complex business. First, universities themselves must approve all 
proposals for submission. Funding agencies then subject those that survive to peer review, a process 
by which a few researchers, usually acting anonymously, assess a proposal’s chances that it will 
achieve its goals, is the best value for money, is relevant to a national priority and will “impact” on a 
socio-economic problem. Only ~25% of proposals received by the funding agencies are funded. These 
protracted processes force researchers to exploit existing knowledge, severely discourage open-ended 
studies and are hugely time-consuming. They are also new: before ~1970, few researchers wrote 
proposals. Now they are virtually mandatory. 
  
Globally, the university sector has expanded three or four-fold since ~1970. However, the 20
th
 century 
was dominated by discoveries made by ~500 Nobel Prize winners, almost all of whom began their 
work before ~1970. Almost all were academics exploring new concepts. Their work led to nuclear 
power; penicillin; lasers; magnetic resonance imaging and monoclonal antibodies. Most were younger 
than 40 when they made their discoveries and few, if any, were predicted. 
  
The potential for discovery now is as great as ever, but we must find new ways of giving 
unconstrained support to the tiny number of scientists with radical agenda. Venture Research was 
British Petroleum’s initiative for supporting such people led by one of us (DWB). It ran from 1980 to 
1993, created at least 14 major discoveries from the 37 groups supported, all of whom, except 
possibly one, had been rejected by peer review. Its total cost, including BP and university overheads, 
was some £20 million over 13 years. Identifying people to lead such initiatives will be difficult but it 
must be done.  
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